First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors
Wei Li, Yongsheng Wang, Anwen Xiong, Ge Gao, Zhengbo Song, Yiping Zhang, Dingzhi Huang, Feng Ye, Qiming Wang, Zhihui Li, Jiaye Liu, Chunwei Xu, Yinghui Sun, Xijie Liu, Fei Zhou, Caicun Zhou · 2024
Read First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors by Wei Li, Yongsheng Wang, Anwen Xiong, Ge Gao, Zhengbo Song, Yiping Zhang, Dingzhi Huang, Feng Ye, Qiming Wang, Zhihui Li, Jiaye Liu, Chunwei Xu, Yinghui Sun, Xijie Liu, Fei Zhou, Caicun Zhou (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11532403.txt.
Description
Wei Li and co-authors report the first human trial of a cancer drug called SY-5007 in a 2024 study. The drug blocks RET, a faulty growth switch found in several cancers, and the trial asked whether it is safe and what dose to carry forward.
A total of 122 patients with advanced RET-changed tumors joined, most with lung cancer or thyroid cancer. Side effects were common, led by high blood pressure and diarrhea, and drug levels rose in step with dose. Among patients whose tumors could be measured, about 58 percent saw their tumors shrink. The results set the dose for the next trial phase and show early promise against RET-driven cancers.
Catalog record
| CREATOR | Wei Li, Yongsheng Wang, Anwen Xiong, Ge Gao, Zhengbo Song, Yiping Zhang, Dingzhi Huang, Feng Ye, Qiming Wang, Zhihui Li, Jiaye Liu, Chunwei Xu, Yinghui Sun, Xijie Liu, Fei Zhou, Caicun Zhou |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |